Clinical trial
Immunotoxin Therapy in Treating Patients With Malignant Glioma
NCT00006268 · New Approaches to Brain Tumor Therapy Consortium, Other · Completed
Key facts
| NCT number | NCT00006268 |
|---|---|
| Title | Immunotoxin Therapy in Treating Patients With Malignant Glioma |
| Official title | Interstitial Infusion of IL 13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study |
| Lead sponsor | New Approaches to Brain Tumor Therapy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Drug, Procedure |
| Interventions | cintredekin besudotox, isolated perfusion, conventional surgery |
| Start date | Oct 1, 2000 |
| Completion | Mar 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: